

Observational study

ALLERGIKA® sensitive in application

ALLERGIKA Pharma GmbH, Wolfratshausen

Summary

Observation period: 2002-2016

Number of participants: 180 private practices

Patients were enrolled who had a clinically relevant and unequivocally diagnosed house dust mite allergy as defined by confirmed sensitivity to house the dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*.

They were each given a set of ALLERGIKA® sensitive encasings (for their mattress, duvet and pillow).

After a mean period of three months' use, a standardized questionnaire was used to determine both the practical features of the encasings as well as the changes in clinical symptoms and medication.

Findings:

- **Practical product features:**

On average, ALLERGIKA® sensitive received the highest possible ranking: "clearly exceeds standards."

64% of those who used ALLERGIKA® sensitive rated it "excellent."

- **Improvement of clinical symptoms:**

On average, ALLERGIKA® sensitive received the highest possible ranking: "clearly exceeds standards."

62% of those who used ALLERGIKA® sensitive rated it "excellent" and observed a conspicuous improvement in their clinical complaints.

- **Reduction of medication:**

54% of those who used it stated they were able to dramatically reduce the amount of medication they needed.

- **Summary / recommendation:**

93% of users stated that they recommended or prescribed ALLERGIKA® sensitive as a key element of avoiding allergens.